Practical Considerations in Using IL-17 Inhibitors for Psoriasis and Psoriatic Arthritis

The presentation discusses practical considerations for using IL-17 inhibitors in the treatment of psoriasis and psoriatic arthritis. Dr. Joe Marola, a dermatologist and rheumatologist, highlights the growing toolkit of IL-17 therapies and emphasizes their rapid efficacy and safety profiles. He reviews various scenarios where IL-17 inhibitors are particularly beneficial, such as patients requiring quick responses or those with moderate to severe psoriatic arthritis. The speaker illustrates the advantages of recent IL-17 agents, including high clearance rates in skin conditions and their effectiveness in treating joint involvement, emphasizing the ability to address both skin and joint symptoms more effectively than traditional TNF inhibitors. Special focus is given to specific skin conditions, such as genital psoriasis and nail disease, and the importance of tailored treatment for patients who have not responded adequately to previous therapies. The potential for dose adjustments in heavier patients is also noted. Safety concerns are addressed, particularly regarding infections, with a recommendation to be cautious in patients with inflammatory bowel disease. Overall, the presentation reinforces the value of IL-17 inhibitors as effective options in managing psoriasis and psoriatic arthritis, with promises for personalized treatment strategies in the future.